Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children

Diagn Microbiol Infect Dis. 2017 Feb;87(2):150-153. doi: 10.1016/j.diagmicrobio.2016.03.001. Epub 2016 Mar 2.

Abstract

The aim of this study was to use a commercially available kit (GenoType® HelicoDR; Hain Life Science, Germany) to detect Helicobacter pylori infection and clarithromycin resistance genotype in biopsies obtained from symptomatic children.

Results: 111 out of 136 (81.6%) biopsies were H. pylori positive by genotype: 47 (42.3%) showed wild-type genotype, 53 resistant genotype (47.7%) and 11 heterogeneous genotype (9.9%). Culture was negative in 27 out of the 111 genotyped biopsies. Mutation A2143G (87.5%), followed by A2142G (7.5%) and double mutant A2142C-A2143G (5%) were found. The 11 heterogeneous genotype biopsies showed wild-type plus A2143G in 9 and plus A2142G in 2.

Conclusions: This kit is a rapid, culture-independent method for routine application in biopsies from the pediatric population that allows detection of clarithromycin resistance and heterogeneous genotypes. It is important to know the clinical impact of infection with this type of strains as well as the role in treatment success.

Keywords: Clarithromycin resistance; Heterogeneous genotypes; Pediatric patients.

Publication types

  • Evaluation Study

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / pharmacology*
  • Biopsy
  • Child
  • Child, Preschool
  • Clarithromycin / pharmacology*
  • Drug Resistance, Bacterial*
  • Female
  • Genetic Variation
  • Genotype*
  • Helicobacter Infections / diagnosis*
  • Helicobacter Infections / microbiology
  • Helicobacter pylori / classification
  • Helicobacter pylori / drug effects*
  • Helicobacter pylori / genetics
  • Helicobacter pylori / isolation & purification*
  • Humans
  • Male
  • Point Mutation

Substances

  • Anti-Bacterial Agents
  • Clarithromycin